Researchers performed a study to examine the molecular-level differences between gluten-associated disorders celiac disease and gluten sensitivity.
Researchers from University of Maryland School of Medicine’s Center for Celiac Research performed a study to examine the molecular-level differences between gluten-associated disorders celiac disease and gluten sensitivity. The study, recently published online in BMC Medicine, found differences in levels of intestinal permeability and the response elicited from the immune system. The researchers say the study provides the first scientific evidence of a different mechanism leading to gluten sensitivity.
The study enrolled gluten-tolerant individuals, as well as those with celiac disease and gluten sensitivity. Intestinal permeability was evaluated using a lactulose and mannitol probe. Mucosal biopsy specimens were collected to study the expression of genes involved in barrier function and immunity.
The researchers said they found that, unlike celiac disease, gluten sensitivity is not associated with increased intestinal permeability. In fact, intestinal permeability was significantly reduced in those with gluten sensitivity compared to controls. Those with gluten sensitivity also showed significantly increased expression of claudin.
In those with celiac disease, relative to controls, adaptive immunity markers interleukin and IL-21 were expressed at higher levels, although they were not in those with gluten sensitivity. Expression of the innate immunity marker Toll-like receptor 2 was increased in those with gluten sensitivity, but not in those with celiac disease. Finally, the expression of the T-regulatory cell marker FOXP3 was significantly reduced in those with gluten sensitivity compared to controls and those with celiac disease.
The researchers say these differences contribute “to the characterization of gluten sensitivity as a condition associated with prevalent gluten-induced activation of innate, rather than adaptive, immune responses in the absence of detectable changes in mucosal barrier function.”
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.